Peripheral Arterial Disease

临床试验

计划入组 126 人 · 首次发布于 2020 年 1 月 14 日

已完成

NCT01407172

Hydrogen Sulfide and Peripheral Arterial Disease

计划入组 252 人 · 首次发布于 2011 年 8 月 2 日

终止

NCT02136537

Electrical Stimulation in Peripheral Arterial Disease

计划入组 40 人 · 首次发布于 2014 年 5 月 13 日

药物

查看全部 1571 →

bioengineered human acellular vessel (peripheral arterial disease)

Peripheral arterial disease cell therapy (MultiGene Vascular Systems)

Small Molecule

Experimental

Levocarnitine propionate

相关疾病：Obliterating Arteriopathy of the Lower Limbs

C₁₀H₁₉NO₄

机构

查看全部 173 →

Bard Peripheral Vascular, Inc.

United States

Rare Disease Research, LLC

CASTLEMAN DISEASE COLLABORATIVE NETWORK

United States

资讯

查看全部 21675 →

2年前

Elixir Medical's DynamX BTK System Receives FDA Breakthrough Device Designation for Chronic Limb-Threatening Ischemia

13年前

Cook Medical's Zilver PTX Becomes First FDA-Approved Drug-Eluting Peripheral Stent in U.S. Market

去年

临床试验

MyPADMGT Support of Out-Patients With Peripheral Arterial Disease

Hydrogen Sulfide and Peripheral Arterial Disease

Electrical Stimulation in Peripheral Arterial Disease

药物

bioengineered human acellular vessel (peripheral arterial disease)

Peripheral arterial disease cell therapy (MultiGene Vascular Systems)

Levocarnitine propionate

机构

Bard Peripheral Vascular, Inc.

Rare Disease Research, LLC

CASTLEMAN DISEASE COLLABORATIVE NETWORK

资讯

Elixir Medical's DynamX BTK System Receives FDA Breakthrough Device Designation for Chronic Limb-Threatening Ischemia

Cook Medical's Zilver PTX Becomes First FDA-Approved Drug-Eluting Peripheral Stent in U.S. Market

PROPHECI Trial Launches to Test Pyrophosphate Treatment for Rare Calcification Disorder PXE